A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors
Small cell lung cancer (SCLC) is an aggressive neuroendocrine subtype of lung cancer with
high mortality. We used a systematic drug repositioning bioinformatics approach querying a …
high mortality. We used a systematic drug repositioning bioinformatics approach querying a …
[HTML][HTML] Rational drug repositioning guided by an integrated pharmacological network of protein, disease and drug
Background The process of drug discovery and development is time-consuming and costly,
and the probability of success is low. Therefore, there is rising interest in repositioning …
and the probability of success is low. Therefore, there is rising interest in repositioning …
[HTML][HTML] Drug repositioning for cancer therapy based on large-scale drug-induced transcriptional signatures
An in silico chemical genomics approach is developed to predict drug repositioning (DR)
candidates for three types of cancer: glioblastoma, lung cancer, and breast cancer. It is …
candidates for three types of cancer: glioblastoma, lung cancer, and breast cancer. It is …
[HTML][HTML] Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypes
CM Bebber, ES Thomas, J Stroh, Z Chen… - Nature …, 2021 - nature.com
Loss of TP53 and RB1 in treatment-naïve small cell lung cancer (SCLC) suggests selective
pressure to inactivate cell death pathways prior to therapy. Yet, which of these pathways …
pressure to inactivate cell death pathways prior to therapy. Yet, which of these pathways …
A framework for identification of actionable cancer genome dependencies in small cell lung cancer
ML Sos, F Dietlein, M Peifer… - Proceedings of the …, 2012 - National Acad Sciences
Small cell lung cancer (SCLC) accounts for about 15% of all lung cancers. The prognosis of
SCLC patients is devastating and no biologically targeted therapeutics are active in this …
SCLC patients is devastating and no biologically targeted therapeutics are active in this …
[HTML][HTML] Heterogeneity of neuroendocrine transcriptional states in metastatic small cell lung cancers and patient-derived models
D Lissa, N Takahashi, P Desai, I Manukyan… - Nature …, 2022 - nature.com
Molecular subtypes of small cell lung cancer (SCLC) defined by the expression of key
transcription regulators have recently been proposed in cell lines and limited number of …
transcription regulators have recently been proposed in cell lines and limited number of …
Systems biology based drug repositioning for development of cancer therapy
Drug repositioning is a powerful method that can assists the conventional drug discovery
process by using existing drugs for treatment of a disease rather than its original indication …
process by using existing drugs for treatment of a disease rather than its original indication …
[HTML][HTML] Drug repositioning for personalized medicine
Human diseases can be caused by complex mechanisms involving aberrations in numerous
proteins and pathways. With recent advances in genomics, elucidating the molecular basis …
proteins and pathways. With recent advances in genomics, elucidating the molecular basis …
[HTML][HTML] A Review of Current In Silico Methods for Repositioning Drugs and Chemical Compounds
B He, F Hou, C Ren, P Bing, X Xiao - Frontiers in Oncology, 2021 - frontiersin.org
Drug repositioning is a new way of applying the existing therapeutics to new disease
indications. Due to the exorbitant cost and high failure rate in developing new drugs, the …
indications. Due to the exorbitant cost and high failure rate in developing new drugs, the …
[HTML][HTML] Changing trends in computational drug repositioning
Efforts to maximize the indications potential and revenue from drugs that are already
marketed are largely motivated by what Sir James Black, a Nobel Prize-winning …
marketed are largely motivated by what Sir James Black, a Nobel Prize-winning …